
Valneva SE (VALN) Stock Forecast & Price Target
Valneva SE (VALN) Analyst Ratings
Bulls say
Valneva SE demonstrated a positive financial outlook with a 13% year-over-year increase in product sales, rising from €144.6 million in 2023 to €163.3 million in 2024. The company reported total revenue of €169.6 million for 2024, marking a 10% increase from the previous year, and further projects substantial growth for its Ixchiq vaccine, estimating sales to surpass €100 million by its third year of launch. Additionally, with the FDA granting accelerated approval for Ixchiq, Valneva is well-positioned to capitalize on a global market for chikungunya vaccines expected to exceed $500 million annually, indicating strong future cash flow potential.
Bears say
Valneva SE is projected to experience a significant decrease in revenue estimates for 2025, declining from €222.5 million to €185 million, while also seeing a downward adjustment in its earnings per share estimate from (€0.53) to (€0.65). The company is attempting to reduce its operating cash burn to below €30 million by 2025, compared to over €60 million in 2024, highlighting ongoing financial strain. Additionally, projected sales for the Ixchiq vaccine have been lowered for fiscal year 2024 to €3 million, with long-term estimates also revised down from €250 million to €225 million for 2029, indicating challenges in meeting sales expectations.
This aggregate rating is based on analysts' research of Valneva SE and is not a guaranteed prediction by Public.com or investment advice.
Valneva SE (VALN) Analyst Forecast & Price Prediction
Start investing in Valneva SE (VALN)
Order type
Buy in
Order amount
Est. shares
0 shares